✦ LIBER ✦

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer

✍ Scribed by Ernest S. Han; Robert A. Burger; Kathleen M. Darcy; Michael W. Sill; Leslie M. Randall; Dana Chase; Basmina Parmakhtiar; Bradley J. Monk; Benjamin E. Greer; Patrick Connelly; Koen DeGeest; John P. Fruehauf

Book ID: 113962603
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 415 KB
Volume: 119
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2010.08.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predictive value of serum CA-125 levels

Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial

✍ Leslie M. Randall; Michael W. Sill; Robert A. Burger; Bradley J. Monk; Barbara B 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 484 KB

A phase II trial of paclitaxel poliglume

A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study

✍ Paul Sabbatini; Michael W. Sill; David O'Malley; Lisa Adler; Angeles Alvarez Sec 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 305 KB

Phase II trial of danazol in advanced, r

Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study

✍ Allan Covens; Virginia L Brunetto; Maurie Markman; James W Orr Jr.; Samuel S Len 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 72 KB

A Gynecologic Oncology Group phase II tr

A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies

✍ Lydia Usha; Michael W. Sill; Kathleen M. Darcy; Doris M. Benbrook; Jean A. Hurte 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 397 KB

Lapatinib and potential prognostic value

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

✍ Kimberly K. Leslie; Michael W. Sill; Heather A. Lankes; Edgar G. Fischer; Andrew 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 723 KB

Phase II trial of combination bevacizuma

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study

✍ E. Alvarez; W. Brady; J. Walker; J. Rotmensch; X. Zhou; J. Kendrick; S. Yamada; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 68 KB